title: Targeted drug delivery in cancer therapy.
abstract: Chemotherapy has been the main modality of treatment for cancer patients; however, its success rate remains low, primarily due to limited accessibility of drugs to the tumor tissue, their intolerable toxicity, development of multi-drug resistance, and the dynamic heterogeneous biology of the growing tumors. Better understanding of tumor biology in recent years and new targeted drug delivery approaches that are being explored using different nanosystems and bioconjugates provide optimism in developing successful cancer therapy. This article reviews the possibilities and challenges for targeted drug delivery in cancer therapy.
authors: Department of Pharmaceutical Sciences, College of Pharmacy, 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA.
authors: Jaspreet K
authors: JK
authors: Vasir
authors: Vinod
authors: V
authors: Labhasetwar
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002352:Carrier Proteins / Q000378:metabolism; D045744:Cell Line, Tumor; D004337:Drug Carriers; D016503:Drug Delivery Systems; D018432:Drug Resistance, Multiple; D004730:Endothelium, Vascular / Q000166:cytology / Q000473:pathology; D058973:Folate Receptors, GPI-Anchored; D005492:Folic Acid / Q000378:metabolism; D018014:Gene Transfer Techniques; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000737:chemistry; D008024:Ligands; D008280:Magnetics; D051379:Mice; D049329:Nanostructures / Q000737:chemistry*; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D009389:Neovascularization, Pathologic; D019301:Oleic Acid / Q000737:chemistry; D011956:Receptors, Cell Surface / Q000378:metabolism; D011973:Receptors, LDL / Q000737:chemistry; D011993:Recombinant Fusion Proteins / Q000737:chemistry; D013997:Time Factors; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D004337:Drug Carriers; D058973:Folate Receptors, GPI-Anchored; D000922:Immunotoxins; D008024:Ligands; D011956:Receptors, Cell Surface; D011973:Receptors, LDL; D011993:Recombinant Fusion Proteins; D019301:Oleic Acid; D005492:Folic Acid; D000068878:Trastuzumab